Ivabradine hydrochloride (Lancora)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of ivabradine 5 mg and 7.5 mg tablets for the treatment of stable chronic heart failure (HF) with left ventricular ejection fraction (LVEF) (d 35%) in adult patients with New York Heart Association...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, June 2017
|
| Series: | CADTH common drug review clinical review report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of ivabradine 5 mg and 7.5 mg tablets for the treatment of stable chronic heart failure (HF) with left ventricular ejection fraction (LVEF) (d 35%) in adult patients with New York Heart Association (NYHA) class II or III HF who are in sinus rhythm with a resting heart rate e 77 bpm, to reduce the incidence of cardiovascular mortality and hospitalizations for worsening HF, administered in combination with standard chronic HF therapies |
|---|---|
| Physical Description: | 1 PDF file (65 pages) illustrations |